Histamine suppresses fibulin-5 and insulin-like growth factor-II receptor expression in melanoma

Cancer Research

Volumn 68, Issue 6, 2008, Pages 1997-2005

  Pos, Zoltan ^a   Wiener, Zoltan ^a   Pocza, Peter ^a   Racz, Melinda ^a   Toth, Sara ^a   Darvas, Zsuzsanna ^a   Molnar, Viktor ^a   Hegyesi, Hargita ^a   Falus, Andras ^a  

^a SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; FIBULIN 5; HISTAMINE; HISTAMINE RECEPTOR; SOMATOMEDIN B RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL MEMBRANE; CONTROLLED STUDY; EXTRACELLULAR MATRIX; FEMALE; GENE CONTROL; GENE EXPRESSION; IMMUNOHISTOCHEMISTRY; MELANOMA; MICROARRAY ANALYSIS; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN PROCESSING; REAL TIME POLYMERASE CHAIN REACTION; TRANSGENIC MOUSE; TUMOR GROWTH;

EID: 40949135821     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-2816     Document Type: Article

References (39)

1. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002;420:860-7.
2. Maeda H, Akaike T. Nitric oxide and oxygen radicals in infection, inflammation, and cancer. Biochemistry (Mosc) 1998;63:854-65.
3. Hudson JD, Shoaibi MA, Maestro R, Carnero A, Hannon GJ, Beach DH. A proinflammatory cytokine inhibits p53 tumor suppressor activity. J Exp Med 1999;190:1375-82.
4. Diegelmann RF, Evans MC. Wound healing: an overview of acute, fibrotic and delayed healing. Front Biosci 2004;9:283-9.
5. Arnott CH, Scott KA, Moore RJ, et al. Tumour necrosis factor-α mediates tumour promotion via a PKCα- and AP-1-dependent pathway. Oncogene 2002;21:4728-38.
6. Muller A, Homey B, Soto H, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001;410:50-6.
7. Strieter RM, Burdick MD, Mestas J, Gomperts B, Keane MP, Belperio JA. Cancer CXC chemokine networks and tumour angiogenesis. Eur J Cancer 2006;42:768-78.
8. Ben Baruch A. Inflammation-associated immune suppression in cancer: the roles played by cytokines, chemokines and additional mediators. Semin Cancer Biol 2006;16:38-52.
9. Jutel M, Blaser K, Akdis CA. The role of histamine in regulation of immune responses. Chem Immunol Allergy 2006;91:174-87.
10. Bartholeyns J, Bouclier M. Involvement of histamine in growth of mouse and rat tumors: antitumoral properties of monofluoromethylhistidine, an enzyme-activated irreversible inhibitor of histidine decarboxylase. Cancer Res 1984;44:639-45.
11. Cricco GP, Davio CA, Martin G, et al. Histamine as an autocrine growth factor in experimental mammary carcinomas. Agents Actions 1994;43:17-20.
12. Tanimoto A, Matsuki Y, Tomita T, Sasaguri T, Shimajiri S, Sasaguri Y. Histidine decarboxylase expression in pancreatic endocrine cells and related tumors. Pathol Int 2004;54:408-12.
13. Haak-Frendscho M, Darvas Z, Hegyesi H, et al. Histidine decarboxylase expression in human melanoma. J Invest Dermatol 2000;115:345-52.
14. Falus A, Hegyesi H, Lazar-Molnar E, Pos Z, Laszlo V, Darvas Z. Paracrine and autocrine interactions in melanoma: histamine is a relevant player in local regulation. Trends Immunol 2001;22:648-52.
15. Hart PH, Grimbaldeston MA, Finlay-Jones JJ. Sunlight, immunosuppression and skin cancer: role of histamine and mast cells. Clin Exp Pharmacol Physiol 2001;28:1-8.
16. Pos Z, Safrany G, Muller K, Toth S, Falus A, Hegyesi H. Phenotypic profiling of engineered mouse melanomas with manipulated histamine production identifies histamine H2 receptor and rho-C as histamine-regulated melanoma progression markers. Cancer Res 2005;65:4458-66.
17. Arentson E, Faloon P, Seo J, et al. Oncogenic potential of the DNA replication licensing protein CDT1. Oncogene 2002;21:1150-8.
18. Richards NG, Kilberg MS. Asparagine synthetase chemotherapy. Annu Rev Biochem 2006;75:629-54.
19. Albig AR, Schiemann WP. Fibulin-5 function during tumorigenesis. Future Oncol 2005;1:23-35.
20. DaCosta SA, Schumaker LM, Ellis MJ. Mannose 6-phosphate/insulin-like growth factor 2 receptor, a bona fide tumor suppressor gene or just a promising candidate? J Mammary Gland Biol Neoplasia 2000;5:85-94.
21. Maloney EK, McLaughlin JL, Dagdigian NE, et al. An anti-insulin-like growth factor I receptor antibody that is a potent inhibitor of cancer cell proliferation. Cancer Res 2003;63:5073-83.
22. Kummola L, Hamalainen JM, Kivela J, et al. Expression of a novel carbonic anhydrase, CA XIII, in normal and neoplastic colorectal mucosa. BMC Cancer 2005;5:41.
23. Hughes AR, Putney JW, Jr. Metabolism and functions of inositol phosphates. Biofactors 1988;1:117-21.
24. Hill SJ, Ganellin CR, Timmerman H, et al. International Union of Pharmacology. XIII. Classification of histamine receptors. Pharmacol Rev 1997;49:253-78.
25. Lim HD, van Rijn RM, Ling P, Bakker RA, Thurmond RL, Leurs R. Evaluation of histamine H1-, H2-, and H3-receptor ligands at the human histamine H4 receptor: identification of 4-methylhistamine as the first potent and selective H4 receptor agonist. J Pharmacol Exp Ther 2005;314:1310-21.
26. del Cuvillo A, Mullol J, Bartra J, et al. Comparative pharmacology of the H1 antihistamines. J Investig Allergol Clin Immunol 2006;16 Suppl 1:3-12.
27. Howden CW, Tytgat GN. The tolerability and safety profile of famotidine. Clin Ther 1996;18:36-54.
28. Kuang PP, Goldstein RH, Liu Y, Rishikof DC, Jean JC, Joyce-Brady M. Coordinate expression of fibulin-5/DANCE and elastin during lung injury repair. Am J Physiol Lung Cell Mol Physiol 2003;285:L1147-52.
29. Hirai M, Ohbayashi T, Horiguchi M, et al. Fibulin-5/DANCE has an elastogenic organizer activity that is abrogated by proteolytic cleavage in vivo. J Cell Biol 2007;176:1061-71.
30. Lau MM, Stewart CE, Liu Z, Bhatt H, Rotwein P, Stewart CL. Loss of the imprinted IGF2/cation-independent mannose 6-phosphate receptor results in fetal overgrowth and perinatal lethality. Genes Dev 1994;8:2953-63.
31. DeChiara TM, Efstratiadis A, Robertson EJ. A growth-deficiency phenotype in heterozygous mice carrying an insulin-like growth factor II gene disrupted by targeting. Nature 1990;345:78-80.
32. Wise TL, Pravtcheva DD. Delayed onset of Igf2-induced mammary tumors in Igf2r transgenic mice. Cancer Res 2006;66:1327-36.
33. Nakamura T, Lozano PR, Ikeda Y, et al. Fibulin-5/DANCE is essential for elastogenesis in vivo. Nature 2002;415:171-5.
34. Yanagisawa H, Davis EC, Starcher BC, et al. Fibulin-5 is an elastin-binding protein essential for elastic fibre development in vivo. Nature 2002;415:168-71.
35. Albig AR, Schiemann WP. Fibulin-5 antagonizes vascular endothelial growth factor (VEGF) signaling and angiogenic sprouting by endothelial cells. DNA Cell Biol 2004;23:367-79.
36. Fortunel NO, Hatzfeld A, Hatzfeld JA. Transforming growth factor-β: pleiotropic role in the regulation of hematopoiesis. Blood 2000;96:2022-36.
37. Kuang PP, Joyce-Brady M, Zhang XH, Jean JC, Goldstein RH. Fibulin-5 gene expression in human lung fibroblasts is regulated by TGF-β and phosphatidylinositol 3-kinase activity. Am J Physiol Cell Physiol 2006;291:C1412-21.
38. Hegyesi H, Horvath B, Pallinger E, Pos Z, Molnar V, Falus A. Histamine elevates the expression of Ets-1, a protooncogen in human melanoma cell lines through H2 receptor. FEBS Lett 2005;579:2475-9.
39. Takahashi K, Tanaka S, Ichikawa A. Effect of cimetidine on intratumoral cytokine expression in an experimental tumor. Biochem Biophys Res Commun 2001;281:1113-9.